Crown Laboratories, a portfolio company of Hildred Capital, has acquired Revance Therapeutics, a Nashville-based provider of dermal fillers. No financial terms were disclosed. Crown is a Johnson City, ...

Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris to develop a ...

Revance’s (RVNC) aesthetic and therapeutic offerings include DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers.

The agreement had made Revance the exclusive commercialization partner for Teoxane’s dermal fillers. After resolving the dispute, Revance and Crown amended their deal, slashing the takeover ...

Revance’s portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers. RHA® technology is proprietary to and manufactured in Switzerland by ...

which granted Revance "the exclusive right to import, market, promote, sell and distribute Teoxane's line of dermal fillers; (ii) the foregoing subjected the Company to an increased risk of ...

which granted Revance "the exclusive right to import, market, promote, sell and distribute Teoxane's line of dermal fillers; (ii) the foregoing subjected the Company to an increased risk of ...

SAN DIEGO, CA and SOUTH SAN FRANCISCO, CA / ACCESS Newswire / January 21, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata") and Revance ...

which granted Revance "the exclusive right to import, market, promote, sell and distribute Teoxane's line of dermal fillers; (ii) the foregoing subjected the Company to an increased risk of ...

The "Crown" logo, PanOxyl and Blue Lizard are registered trademarks of Crown Laboratories, Inc. SkinPen and StriVectin are registered trademarks of Bellus Medical, LLC and StriVectin Operating Company ...